Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats
Authors:
- Xiang-Rong ZuoXZXiang-Rong Zuo
- Yan-Yan WangYWYan-Yan Wang
- Wei-Ping XieWXWei-Ping Xie
- Hong WangHWHong Wang
- Miaojia ZhangMZMiaojia Zhang
- 1 January 2013
- journal article
- Published by Elsevier in Vascular Pharmacology
- Vol. 58 (1-2) , 71-77
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (NSFC no. 30971319)
- national “eleven, five” science and technology support program (2008BAI59B02)
- “Six Talent Peak” Project of Jiangsu Province (08-B, WX)
This publication has 21 references indexed in Scilit:
- Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in ratsEuropean Respiratory Journal, 2010
- The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targetedProceedings of the National Academy of Sciences, 2007
- Mycophenolate mofetil attenuates pulmonary arterial hypertension in ratsBiochemical and Biophysical Research Communications, 2006
- Infliximab Treatment in a Patient with Systemic Sclerosis Associated with Lung Fibrosis and Pulmonary HypertensionRespiration, 2005
- Reversal of experimental pulmonary hypertension by PDGF inhibitionJournal of Clinical Investigation, 2005
- Cellular and molecular pathobiology of pulmonary arterial hypertensionJACC, 2004
- Inflammation in pulmonary arterial hypertensionEuropean Respiratory Journal, 2003
- Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?Annual Review of Immunology, 2001
- TNF-α antagonists for the treatment of Crohn’s diseaseExpert Opinion on Pharmacotherapy, 2000
- Etanercept in Children with Polyarticular Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 2000